Clinical Trial Update: Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Pycnogenol for cardiac fibrosis and diastolic dysfunction in aged hypertensive subjects has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Fibrosis
• Diastolic Dysfunction

Drugs mentioned

• Pycnogenol (French maritime pine bark extract (Pinus pinaster bark extract))

Snippet

Sponsor: University of Arizona | Conditions: Cardiac Fibrosis, Diastolic Dysfunction | Phase 2 | Status: TERMINATED